SCHEMBL6789227

SCHEMBL6789227

O=C(Nc1ccc(NCCc2ccccn2)cc1)c1ccccc1-c1ccc(O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
HTT P42858 3/20 0.50
SMO Q99835 2/20 0.48
ALDH1A1 P00352 1/20 0.48
CHRNB2 P17787 2/20 0.47
CHRNB4 P30926 2/20 0.47
CHRNA3 P32297 2/20 0.47
CHRNA4 P43681 2/20 0.47
KDM4E B2RXH2 2/20 0.46
MEN1 O00255 2/20 0.46
MAPT P10636 2/20 0.46
KMT2A Q03164 2/20 0.46
GAA P10253 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CNR1 P21554 1/20 0.46
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.46
GLA P06280 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
TAS1R3 Q7RTX0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6791511 0.92 HTT (0.57) LMNAHTTSMOALDH1A1CHRNB2
SCHEMBL6796673 0.92 HTT (0.59) LMNAHTTSMOALDH1A1CHRNB2
SCHEMBL6792583 0.91 KMT2A (0.56) LMNAHTTSMOALDH1A1CHRNB2
SCHEMBL6793890 0.90 RAB9A (0.54) LMNAHTTSMOALDH1A1CHRNB2
SCHEMBL6794915 0.90 LMNA (0.49) LMNAHTTSMOALDH1A1CHRNB2
SCHEMBL6787263 0.90 HTT (0.49) LMNAHTTSMOALDH1A1CHRNB2
SCHEMBL6788981 0.90 HTT (0.49) LMNAHTTSMOALDH1A1CHRNB2
SCHEMBL6794391 0.90 HTT (0.49) LMNAHTTSMOALDH1A1CHRNB2
SCHEMBL6793707 0.90 CNR1 (0.58) LMNAHTTSMOALDH1A1CHRNB2
SCHEMBL6798643 0.90 ALDH1A1 (0.58) LMNAHTTSMOALDH1A1CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 LMNA 1239/4885HTT 2566/4885SMO 2094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.